


FiercePharma Select another site | Advertise | Contact SEARCH



Free Daily Pharma Industry Newsletter Every business day, *FiercePharma* updates pharmaceutical executives on the latest Pharma industry news and deals. Stay up to date on:

Pharma Company News | Generic Drug Companies | Pharmaceutical Marketing & Sales | FDA Regulations & Warnings | Phase IV Clinical Trials

[Click here](#) to see a sample.

We never sell or give away your contact information. Our readers' trust comes first.

FiercePharma NEWS TOPICS ANALYSIS FEATURES LIBRARY EVENTS JOBS MARKETPLACE

FOLLOW US

Topics: [Financials](#)


Roche's 'blowout' cancer launches help fuel 10% profits hike

July 25, 2013 | By [Tracy Staton](#)

SHARE Fueled by a "blowout" launch of its new breast-cancer drug [Kadcyla](#), Roche ([\\$RHHBY](#)) posted a 10% hike in profits for the first half of the year, on sales that topped analyst estimates at 7.58 billion Swiss francs, or about \$8 billion. The rest of Roche's cancer portfolio delivered, too, with top-selling Rituxan bringing home 1.7 billion francs.

Approved by the FDA in February, Kadcyla brought in 65 million francs, or about \$69.5 million, for the second quarter, Kepler Cheuvreux analyst Fabian Wenner told *Bloomberg*. For the entire half-year--the figures Roche reported today--Kadcyla garnered global sales of 83 million francs. Another new breast cancer treatment, [Perjeta](#), approved by the FDA last November, accounted for 108 million francs.

"It was a blowout result," Wenner told the news service of Kadcyla's sales.



Roche CEO Severin Schwan

Webinar: Leveraging Metabolite Biomarkers for Clinical Trials

DATE: THURSDAY, OCTOBER 30, 11 AM ET / 8 AM PT

This webinar will introduce a robust, highly sensitive biomarker development program that leverages the revolutionary metabolomics discovery platform and expands the menu of compounds that can be measured routinely and reliably. [Register Now!](#)

TOOLS

Comment [Sign up for our FREE newsletter for more news like this sent to your inbox!](#)

Print Roche needs new products to kick in as it prepares for biosimilar competition to its gold-standard older drugs, including [Rituxan](#), a treatment for blood cancers and autoimmune disease, and [Herceptin](#), the breast cancer therapy, which brought in 1.55 billion francs for the period. That's 3.25 billion francs at risk, or about \$3.5 billion. Analysts are expecting biosimilars to hit in the U.S. as soon as 2015, but Roche now says it sees Rituxan biosims waiting till 2016.

Contact Author

Reprint Roche has been pushing beyond cancer, with R&D efforts in asthma, diabetes and Alzheimer's disease, among others. Its success has been limited so far; pharma chief [Daniel O'Day](#) noted today during the earnings call that the

JOIN 150,000+ INSIDERS SIGN UP FOR OUR NEWSLETTER

FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join thousands of pharma industry leaders who get *FiercePharma* via daily email. Sign up today!

FiercePharma

Join our network of over 270,000 readers in the life sciences industry

SIGN UP NOW!

POPULAR STORIES

MOST READ | **MOST SHARED**

Don't fire me, Sanofi CEO tells board, amid tussle over strategy

UPDATED: Looming trouble in Sanofi's diabetes biz turns up the heat on CEO

Pharma's top 10 M&A deals of 2014's first half

Sanofi canned its outspoken CEO. Will the board go French with a replacement?

Pfizer's Q3 beats, but flat sales mean CEO Read needs a big move

THE LIBRARY: EBOOK

Special Report | [The Changing Landscape of Phase IV Research](#)

| PUBLISHED: SEPTEMBER 29, 2014 | SPONSORED BY: COVANCE

company may abandon heart and metabolic diseases completely. "We are still deciding," he said (as quoted by *Bloomberg*).

What else can Roche do to prep for competition? Deals, of course. The company is said to be eyeing a deal for Alexion Pharmaceuticals ([\\$ALXN](#)), the U.S.-based rare-disease specialist that reaps billions from small patient populations. Its [Soliris](#) treatment for two rare diseases brought in \$1.13 billion last year. Though Roche CEO [Severin Schwan](#) wouldn't comment on a potential Alexion deal, he did say the company is eyeing bolt-on buyouts.

"As far as our overall innovation strategy is concerned there is no change," Schwan said (as quoted by *Reuters*). "It has always been our strategy to have internal and external innovation. ... [W]e will continue to focus on bolt-on acquisitions."

- see the Roche earnings [release](#)
- get [more](#) from *Bloomberg*
- check out the *Reuters* [news](#)
- here's [more](#) on diagnostics sales from *FierceMedicalDevices*

Special Reports: [The Roche billionaires - Fierce's 10 top biotech billionaires](#) | [Top 10 Best-selling Cancer Drugs](#) | [Top Pharma Companies by 2012 Revenues](#)

Related Articles:

- [Roche casts its net \(again\) for the perfect chairman](#)
- [Roche may want Alexion, but is the price right?](#)
- [With nod, Roche's Kadcyla should quickly become blockbuster](#)
- [FDA approves Roche's pricey new Herceptin partner, Perjeta](#)
- [No stock buybacks for Roche. Let's make a \\$7B deal instead](#)

Sign up for our free newsletter

Filed Under [Kadcyla](#), [Roche](#)

COMMENTS

Industry spending on post-authorization studies belies the rapid changes occurring in Phase IV research, driven by an the demand for evidence of safety and effectiveness. [Download this Special Report](#) to learn how Phase IV research continues to transform.

[MORE ITEMS](#)

LATEST COMMENTARY

[Cancer survivor's petition pleads with Roche for lower Kadcyla price](#)

[Merck hops onto HBCU network to step up its brand in the African-American community](#)

[Sunshine fact: \\$3.5B + 546,000 docs equals one unwieldy database](#)

[Copay coupons get the Inspector General treatment](#)
[First-to-market launch? Bonus--but double bonus if you're Big Pharma](#)

EVENTS

Human Abuse Liability & Abuse-Deterrent Formulations Summit
Nov 17-18 — Silver Spring, MD — Sponsored by: ExL Pharma

3rd Content Marketing for Life Sciences
December 4-5 — Philadelphia, PA — Sponsored by: ExL Pharma

Clinical Performance Metrics & Benchmarking
December 12-13 — Philadelphia, PA

[MORE EVENTS](#)

0 Comments
FiercePharma
Login

Sort by Best
Share
Favorite

Be the first to comment.

PRESS RELEASES

Abbott Expands Its Medical Device Business wi Catheter-Based Electrophysiology Market

CSL Behring Signs Strategic Development Agre Injections To Market Novel New Drug Delivery C pSivida Corp (PSDV) Pockets \$25 Million Milest

ZOLL Announces Acquisition of the Assets of li Inc.

Inogen (INGN) Announces Launch Of Proposed Offering By Selling Stockholders

[More Press Releases](#)

FEATURED JOBS

> Need a job? Need to hire? Visit our jobs site.

ALSO ON FIERCEPHARMA

Orphan drug prices on non-orphan meds? Gilead, this means you, ...

1 comment • a day ago

3Tavgreg — Yeah but Harvoni is a cure, orphan drugs are not. I think you're more worried about your own profits ...

Payers hit back at Gilead for \$94,500 price tag on brand-new hep C ...

6 comments • 16 days ago

georgebeach — OUTRAGEOUS!

WHAT'S THIS?

GSK dealmaking spawns management shake-up, putting ...

1 comment • 7 days ago

48vince — I heard that heads were rolling at GSK ...

India's NPPA fines Novartis \$49M as price cap battles rage on

1 comment • 16 days ago

AAN — Good job NPPA , put these scums in line

Subscribe
Add Disqus to your site
Privacy

A publication of

FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get *FiercePharma* via daily email. [Click here](#) to get your free weekly email briefing today!

The FierceMarkets Network:

Telecom
 FierceCable
 FierceDeveloper
 FierceWireless:Europe
 FierceWirelessTech
 FierceOnlineVideo
 FierceTelecom
 FierceWireless

Marketing & Retail
 FierceCMO
 FierceMobileMarketer
 FierceRetail
 FierceRetailIT
 FierceMobileRetail

Healthcare
 FierceEMR
 FierceHealthcare
 FierceHealthFinance
 FierceHealthIT
 FierceHealthPayer
 FierceHealthPayerAntiFraud
 FierceMedicalImaging
 FierceMobileHealthcare
 FiercePracticeManagement
 Hospital Impact

Government
 FierceGovernment
 FierceGovernmentIT
 FierceHomelandSecurity
 FierceMobileGovernment

Life Sciences
 FierceBiotechResearch
 FierceBiotech
 FierceBiotechIT
 FierceCRO
 FierceDiagnostics
 FierceDrugDelivery
 FierceMedicalDevices
 FiercePharma
 FiercePharmaManufacturing
 FiercePharmaMarketing
 FierceVaccines
 FierceAnimalHealth

Enterprise IT
 FierceBigData
 FierceCIO
 FierceContentManagement
 FierceEnterpriseCommunicatio
 FierceITSecurity
 FierceMobileIT

Energy
 FierceEnergy
 FierceSmartGrid

Finance
 FierceCFO
 FierceFinanceIT

Home | [Subscribe](#) | [Manage Newsletter Subscriptions](#) | [Advertise](#) | [Contact](#) | [Mobile Apps](#) | [RSS](#) | [Privacy](#) | [Editors](#) | [List in Marketplace](#)

© 2014 FierceMarkets, a division of Questex Media Group LLC. All rights reserved.